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Summary.-Seventy patients with Hodgkin's disease have been treated with a
combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
The complete remission rate of75-7% compares well with that produced by other
combinations. The combination is non-toxic, easily administered and can be given
safely to outpatients. Its main advantage is that it is far less upsetting to patients
than combinations containing nitrogen mustard.
THE MOPP (mustine, vincristine, pro-
carbazine and prednisone) combination for
the treatment of advanced Hodgkin's
disease, introduced by De Vita, Serpick
and Carbone in 1970, is the standard by
which combination chemotherapy is
judged in this disease. Vinblastine was
substituted for vincristine to give MVPP
(Nicholson et al., 1971; McElwain et al.,
1973). This combination gives the same
remission rate and overall survival as
MOPP, and has the advantage over
MOPP ofproducing less neurotoxicity and
epilation. However, MVPP retains a major
side-effect also present in MOPP: the
nausea and vomiting induced by nitrogen
mustard. This is frequently so severe that
patients need admission to hospital and
heavy sedation. Also, nitrogen mustard
must be given in a fast-running saline drip
to prevent damage to veins. This results
in the immobilization of the patient and
is time-consuming for medical and nursing
staff.
Since increasing numbers of patients
with Hodgkin's disease are being treated
with combination chemotherapy both as
primary treatment and as an adjunct to
radiotherapy, we felt that there was a need
for a combination which could simply and
safely be given to outpatients without the
need for supplying a drip and without
making them vomit. We therefore decided
to replace the nitrogen mustard in the
MVPP combination with oral chloram-
bucil, 6 mg/M2 daily for 14 days, not
exceeding a dose of 10 mg/day. Chloram-
bucil in this dosage causes few if any ill
effects, and in particular does not produce
epilation or haemorrhagic cystitis, as is
the case with i.v. cyclophosphamide,
which has also been used as an alternative
to nitrogen mustard. Our other reasons
for choosing chlorambucil are summarized
below:
(i) Chlorambucil as a single agent
produces complete remission rates
(16%) in Hodgkin's disease equi-
valentto those obtained withnitro-
gen mustard alone (13%) (Carter
and Goldsmith, 1976 cumulative
data).
(ii) In combination with vinblastine,
chlorambucil has produced a 60%
complete remission rate in ad-
vanced Hodgkin's disease (Lacher
and Durant, 1965).TREATMENT OF HODGKIN'S DISEASE
(iii) Experimental studies (Harrap
et al., 1975) have shown that the
antitumour effect of chlorambucil
is potentiated by steroids.
(iv) Combinations of chlorambucil and
corticosteroids have been shown
to be more effective than chloram-
bucil alone for the treatment of
lymphoproliferative diseases in
man (Ezdinli and Stutzman, 1965).
PATIENTS AND METHODS
Treatment.-Details of the combination
(Ch1VPP) are shown below:
Chlorambucil 6 mg/M2 (orally) daily on
Days 1 to 14, not exceeding a dose of
10 mg/day.
Vinblastine 6 mg/M2 (i.v.) on Days 1 and 8,
not exceeding a single dose of 10 mg.
Procarbazine 100 mg/M2 (orally) on Days
1 to 14 inclusive.
Prednisolone 40 mg (orally) daily on Days
1 to 14 inclusive in adults, making
appropriate dose reductions for children.
Each course of treatment lasted 2 weeks,
with a 2-week rest period between courses.
The total number of courses was determined
from the response to treatment. Courses
were given until complete remission occurred.
After this in most cases a further 5 courses
were given. If complete remission did not
occur after the first 5 courses, the disease
was considered resistant to ChlVPP and the
treatment changed. Thus a minimum of 6
and a maximum of 10 courses were given to
patients who achieved complete remission.
No "maintenance" chemotherapy was given
after this.
Patients-.Seventy patients with Hodgkin's
disease have completed treatment and are
available for analysis. There were 47 males
and 23 females ranging in age from 3 to 76
years. Mean age was 28 years and median age,
27 years (males-mean 28, median 26;
females-mean 28, median 29).
Histology.-Histological classification was
by the criteria of Lukes and Butler (1966).
A total of 39 (560%) had nodular sclerosis
(NS), 24 (34%0) had mixed cellularity (MC),
4 (6%) had lymphocyte predominance (LP)
and 3 (4Oo) had lymphocyte depletion (LD).
The 4 patients with LP were males; 21
(54%) ofthe patients with NS were males and
18 (460%) were females; 21 (88%) of the
patients with MC were males and 3 (12%)
were females; one patient with LD was
male and 2 were females. Of the 47 male
patients, 4 (S8%) had LP, 21 (45 0) had NS
and 1 (2%) had LD. Of the 23 females, none
had LP, 3 (13%) had MC, 18 (785o) had NS
and 2 (9%0) had LD.
Previous treatment.-Thirty-six patients
had received no previous treatment (NPT).
These were either Stage III or IV patients in
whom chemotherapy was the primary treat-
ment, or patients with earlier-stage disease in
whom chemotherapy was given electively to
achieve complete remission prior to radio-
therapy. Twenty-two patients had relapsed
followingradiotherapy (PRT), and 12 patients
had relapsed following previous chemo-
therapy plus or minus previous radiotherapy
(CT±RT). Details ofthese patients are given
in Table I.
Stage of disease.-The Ann Arbor staging
system was used (Carbone et al., 1971).
Details of clinical staging investigations have
been reported previously (McElwain et al.,
1973). Twenty-four patients wN-ere clinically
TABLE I. Distribution of Patients by Previous Treatment, Sex and Age
Age (years)
No. of
Group patients Male (o%) Female (o%) Mlean AMe(lian
No previous treatment
(NPT)
Previous radiotherapy
(PRT)
Previous chemotherapy±
radiotherapy (CT±RT)
Total
36 30 (83uo)
22 10 (45%)
12 7 (580 %)
70 47 (67 %) 23 (33%)
6 (17%)
12 (550/)
5 (42%)
24 8
34.3
25-5
25
30
26 5
277
28 27278 T. J. McELWAIN, J. TOY, E. SMITH, M. J. PECKHAM AND D. E. AUSTIN
staged (CS) and 46 patients were patho-
logically staged (PS) by laparotomy with
splenectomy and lvmph node, liver and bone
biopsv specimens (Gazet, 1973). Distribution
of patients by clinical and pathological stage
is shown in Table H, with remission data for
each stage.
RESULTS
Remission rates
Complete remission was defined as
complete disappearance of all measurable
evidence of disease, with resolution of all
symptoms, and laboratory evidence sug-
gesting Hodgkin's disease.
Partial remission was defined as at least
50% reduction of the diameter of measur-
able lesions in 2 planes at right angles to
one another, associated with an improve-
ment in the patient's general condition,
and abolition of any symptoms specific to
Hodgkin's disease.
Failure is synonymous with continuing
disease activity.
The overall complete remission rate was
75-7O%, complete plus partial remission
rate was 93%. Only 7% of patients com-
pletely failed to respond to treatment.
The complete remission rate of 75-7%
compares well with the complete remission
rate of 76-6% previously reported by us
for MVPP (McElwain et al., 1973).
Table II shows remission rates for each
stage, and Table III shows details of
remission rates for the 3 treatment groups
of patients. Percentages in parentheses in
Table III are the complete remission rates
for the previously reported MVPP-treated
patients. As in the MVPP series, the
highest remission rate (91%) was seen in
the group who had previously received
radiotherapy, and may reflect the fact
that many of these patients had a rela-
tively small volume of disease at the time
of starting chemotherapy. In the group
who had received previous chemotherapy
± radiotherapy, all the patients had
received MVPP, so it is perhaps not
surprising that only 7/12 patients achieved
complete remission with a combination
TABLE II.-Distribution of Patients by Stage Prior to Treatment uith Ch1 VPP
Number Number
achieving achieving
Clinically complete Pathologically complete
staged remission staged remission
1
0
4
2
6
4
5
24
0
0
2
1
5
5
17
0
0
.2
6
17
5
46
0
1
5
15
5
3
36
Total
achieving
complete
Total remission
1
6 6
8
23
9
12
,O
0
0
3
6
20
7
8
53
TABLE III.-Respoase to Treatment uith Chl VPP. In Parentheses; Remission
Ratesfor MVPP (McElwain et al., 1973)
Complete
remission
Group Nutimber 0°
NPT
PRT
CT=RT
Total
26/36
20/22
7/12
53/70
72 (78)
91 (87)
58 (66)
75-7 (76-61
Partial
remission
Number %
9/36
1/22
2/12
12/70
25
4.5
17
17
Failed
Xumber 0O
1/36
1/22
3/12
5/70
3
4.5
25
7
Stage
LX
IB
ILA,
IIB
IIIB
IVA
IVB
Total
MIean no. of
courses to
achieve
complete
remission
3-9
2-1
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which onlv differed from MVPP bv one
drug substitution. Complete remission
rates by histological grade of disease were
as follows: LP, 500 (2/4), NS 900o
(35/39), MC 79% (19/24), LD none (0/3).
In patients under 40 years, the complete
remission rate was 81% (46/57) and in
those over 40 it was 54% (7/13). The
presence or absence of symptoms specific
for Hodgkin's disease (fever, weight loss
and sweating) had no influence upon
remission rates, which were 770% (31/40)
for "A" cases (no symptoms) and 73%o
(22/30) for "B" cases (symptoms). Com-
parative figures for MYPP-treatedpatients
are A-81i00 and B-74%
Drug dosage and toxicity
The combination is remarkably non-
toxic. Injections of vinblastine were
routinely given in the outpatient depart-
ment and after treatment nearly all adult
patients could return home unaccom-
panied. No patient was admitted to
hospital specifically for chemotherapy,
although some were in hospital for other
reasons when chemotherapy was started.
Paraesthesiae due to vinblastine
developed in a patients, but was never
disabling. Five patients became constip-
ated, but this could easily be relieved with
milk of magnesia and liquid paraffin. Six
patients noted some hairfall but none was
epilated to the point where it was socially
noticeable. Nineteen patients reported
some nausea while taking the tablets:
this was probably due to the procarbazine,
and could be ameliorated with pheno-
thiazine antiemetics. Six patients vomited
after the Day 1 injection of vinblastine,
but not after the Day 8 injection, and this
did not occur with every course of treat-
ment. The majoritv ofpatients suffered no
nausea or vomiting, and routine prophy-
lactic antiemetics were not given. Two
women developed amenorrhoea and 2
patients noticedexacerbation ofacnewhile
taking prednisolone. One woman develop-
ed a steroid myopathy which totally
resolved after completion of treatment.
No patient refused treatment.
MIany patients received their Dav 8
injection of vinblastine from their own
general practitioner, which meant that
they had only had to attend hospital
outpatients once a month.
Bone marrow toxicity has not been a
problem, dose-reduction being necessary
in only a few patients. In 15 patients on
22 occasions, it was decided to delay the
start of a course oftreatment because of a
depression of leucocyte or platelet count
(WtBC < 3,000/mm3, platelets < 80,000/
mm3) In 9ofthese patients, delaywasonly
necessary on one occasion, and of the
remaining 6, 5 had had previous treat-
ment which probably compromised their
bone marrow. A delav of more than 2
weeks was only necessarv on 2 occasions.
Table IV shows the mean percentage of
the calculated dose of each drug which
could be administered to the 3 groups of
patients during their entire programme of
treatment. In all 3 groups, more than
950o of the calculated dose of each drug
could be given.
FoUow-up
The study began in January, 1975, and
the first patient completed treatment in
July, 1975. Maximum post-treatment
follow-up time is 18 months and minimum-
follow-up time is 6 months, so clearly it is
too early fully to assess the effect of
treatment on the survival of the entire
group. In the "No Previous Treatment"
group, 2 patients have relapsed, 1 with a
bone metastasis and 1 with a paravertebral
mass. Both have responded to radio-
TABLE IV.-Calculed Dose of Drug
Administered as 00 ofFull Programme of
Treatment
Previous
No chemotherapy
previous Previous
Drug treatment radiotherapy radiotherapy
Chlorambucil
Vinblastine
Procarbazine
Prednisolone
99-6
98 8
96-2
99-8
97-1
95.4
96 1
99-6
99.4
97.9
95-7
96-8
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therapy and remain alive and well. Two
patients have died. Neither had achieved
complete remission. One, a child of 3 with
MC disease in partial remission, developed
Pneumocystis carinii pneumonia after 6
courses of treatment. He failed to respond
to treatment with both pentamidine and
cotrimoxazole. This is the first time we
have seen this complication in a patient
with Hodgkin's disease, although it is
becoming increasingly common in children
receiving chemotherapy for acute leuk-
aemia. At a speculative level, it may be
significant that he was followed up in a
clinic with large numbers of leukaemic
children who could constitute a reservoir
of infection. In the "Previously Irradi-
ated" group, there has been one death
after failure to respond. In the "Previous
Chemotherapy ± Radiotherapy" group,
one patient relapsed 3 months after
cessation oftreatment. She had previously
received MVPP, so it is perhaps not
surprising that her response to ChlVPP
was short-lived.
DISCUSSION
ChlVPP is a non-toxic, easily tolerated
regime, which gives remission rates equiv-
alent to those of MOPP or MVPP. The
speed of response is also the same as that
for combinations containing nitrogen
mustard. This surprised us, since chloram-
bucil alone produces responses more
slowly than nitrogen mustard alone.
The combination is well suited to use in
outpatients and has meant that no patient
has required admission to hospital for
chemotherapy. This is particularly impor-
tant in the case of children; there were 9
patients below the age of 13 in this series,
and all tolerated their treatment well.
There is a real need for a non-toxic
combination for treating Hodgkin's
disease, particularly in view of the
increasing tendency to combine chemo-
therapy and radiotherapy in the manage-
ment of many patients. It is important
that these patients should not be asked
to bear more unpleasant side-effects from
this protracted treatment than is abso-
lutely necessary. Although we cannot yet
know what the effect of ChlVPP will
be on the long-term survival of patients
treated with chemotherapy alone, we
feel that the combination is a safe and
easy way of treating patients in whom
chemotherapy is used as an adjuvant
either before or after radiotherapy and
would confidently recommend it for this
purpose. We are confident from our
experience to date that Ch1VPP provides
a good alternative to MVPP and deserves
further study in relapsed patients and
previously untreated late-stage patients.
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